看多
Ritter Pharmaceuticals - RTTR Fundamental Analysis
The market seems to go up, mainly based on the merger with Qualigen - ( I did not find any other news regarding this stock)
Qualigen should become a wholly-owned subsidiary of Ritter.
Upon completion of the merger, Ritter will change its name to Qualigen Therapeutics, Inc., and will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its revenue-generating diagnostic business.
The special meeting of Ritter stockholders to vote on certain matters related to the proposed merger will be held virtually on May 14, 2020.
Qualigen should become a wholly-owned subsidiary of Ritter.
Upon completion of the merger, Ritter will change its name to Qualigen Therapeutics, Inc., and will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its revenue-generating diagnostic business.
The special meeting of Ritter stockholders to vote on certain matters related to the proposed merger will be held virtually on May 14, 2020.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。